Search results
Results From The WOW.Com Content Network
On December 9, 2016, pharmaceutical company Bristol-Myers Squibb agreed to pay $19.5 million to settle claims with forty-three state attorneys general concerning the alleged off-label promotion of its schizophrenia drug Abilify. [50] The lawsuit alleged the company promoted the drug for use in pediatric populations and to treat dementia and ...
Legal claims against the pharmaceutical industry have varied widely over the past two decades, including Medicare and Medicaid fraud, off-label promotion, and inadequate manufacturing practices. [ 3 ] [ 4 ] With respect to off-label promotion, specifically, a federal court recognized off-label promotion as a violation of the False Claims Act ...
The FTC sued UnitedHealth Group's Optum unit, CVS Caremark and Cigna's Express Scripts for allegedly steering diabetes patients towards higher priced insulin.
For example, Purdue Pharmaceuticals entered an agreement with the United States, pleading guilty to felony misbranding of OxyContin with intent to defraud and mislead under sections 33 1(a) and 333(a)(2) of the FD&C Act and agreed to pay more than $600 million, but only $160 million was allocated to resolve civil claims under the False Claims ...
CVS and Walgreens. $10.7 billion. CVS and Walgreens have agreed to settle lawsuits brought against the companies by several states for their alleged role in the opioid crisis. CVS would pay nearly ...
The four patients from Clackamas County, identified in the lawsuit by their initials, underwent surgeries at Providence Willamette Falls Medical Center in Oregon City between March 2022 and ...
In lawsuits and complaints with state law enforcement officials, hospice families claim their directives were ignored and that loved ones received too many medications, or not enough. The most-watched federal lawsuit, filed last May, accuses Vitas in unusually strong language of harming patients in the pursuit of profits.
Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.